Rurioctocog alfa pegol - Shire

Drug Profile

Rurioctocog alfa pegol - Shire

Alternative Names: Adynovate; Adynovi; Antihemophilic Factor (Recombinant), PEGylated - Shire; BAX-855; EHL rFVIII PEG; Extended half-life recombinant FVIII; Full-length longer-acting rFVIII; LA rFVIII PEG; PEG factor VIII - Shire; PEGylated recombinant factor VIII; PEGylated rFVIII

Latest Information Update: 28 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Baxter International; Nektar Therapeutics
  • Developer Shire
  • Class Antihaemorrhagics; Blood coagulation factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilia A

Most Recent Events

  • 09 Nov 2017 The Committee for Medicinal Products for Human Use recommends approval of Rurioctocog alfa for Haemophilia A (In adolescents, In children, In infants, In neonates, Treatment-experienced, In adults) in European Union (IV)
  • 22 Mar 2017 Launched for Haemophilia A (In adolescents, In children, Treatment-experienced, In adults) in Australia (IV) after March 2017
  • 21 Mar 2017 Registered for Haemophilia A (In adolescents, Treatment-experienced, In adults, In children) in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top